OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!
If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.
Requested Article:
Sodium Glucose Cotransporter 2 (SGLT2) Inhibitors and CKD: Are You a #Flozinator?
Anoushka Krishnan, Mythri Shankar, Edgar V. Lerma, et al.
Kidney Medicine (2023) Vol. 5, Iss. 4, pp. 100608-100608
Open Access | Times Cited: 8
Anoushka Krishnan, Mythri Shankar, Edgar V. Lerma, et al.
Kidney Medicine (2023) Vol. 5, Iss. 4, pp. 100608-100608
Open Access | Times Cited: 8
Showing 8 citing articles:
The Renoprotective Mechanisms of Sodium-Glucose Cotransporter-2 Inhibitors (SGLT2i)—A Narrative Review
Liana Iordan, Laura Gaiță, Romulus Timar, et al.
International Journal of Molecular Sciences (2024) Vol. 25, Iss. 13, pp. 7057-7057
Open Access | Times Cited: 6
Liana Iordan, Laura Gaiță, Romulus Timar, et al.
International Journal of Molecular Sciences (2024) Vol. 25, Iss. 13, pp. 7057-7057
Open Access | Times Cited: 6
Cost-effectiveness of add-on empagliflozin versus standard of care in management of CKD in Malaysia, Thailand and Vietnam – findings from a modelling study assessing an EMPA-KIDNEY eligible population, using CKD progression model.
Lijoy Varghese, Poh Wan Chang, Sorrakorn Juntarasiripas, et al.
Journal of Medical Economics (2024) Vol. 27, Iss. 1, pp. 836-848
Open Access | Times Cited: 3
Lijoy Varghese, Poh Wan Chang, Sorrakorn Juntarasiripas, et al.
Journal of Medical Economics (2024) Vol. 27, Iss. 1, pp. 836-848
Open Access | Times Cited: 3
A Drug Safety Evaluation of Dapagliflozin for Diabetic Nephropathies in Patients with Cardiovascular Risk
Aayushi Sood, Aanchal Sawhney, Benjamin Borokhovsky, et al.
Expert Opinion on Drug Safety (2025)
Closed Access
Aayushi Sood, Aanchal Sawhney, Benjamin Borokhovsky, et al.
Expert Opinion on Drug Safety (2025)
Closed Access
Sodium-Glucose Co-Transporter 2 Inhibitors as a Powerful Cardioprotective and Renoprotective Tool: Overview of Clinical Trials and Mechanisms
Andrej Belančić, Sanja Klobučar Majanović
Diabetology (2023) Vol. 4, Iss. 3, pp. 251-258
Open Access | Times Cited: 8
Andrej Belančić, Sanja Klobučar Majanović
Diabetology (2023) Vol. 4, Iss. 3, pp. 251-258
Open Access | Times Cited: 8
Emerging Preventive Strategies in Chronic Kidney Disease: Recent Evidence and Gaps in Knowledge
Nishigandha Pradhan, Mirela Dobre
Current Atherosclerosis Reports (2023) Vol. 25, Iss. 12, pp. 1047-1058
Closed Access | Times Cited: 2
Nishigandha Pradhan, Mirela Dobre
Current Atherosclerosis Reports (2023) Vol. 25, Iss. 12, pp. 1047-1058
Closed Access | Times Cited: 2
SGLT2 inhibitors for treatment of chronic kidney disease
Scott L. Davis
SA pharmaceutical journal. (2024) Vol. 91, Iss. 2, pp. 26-28
Closed Access
Scott L. Davis
SA pharmaceutical journal. (2024) Vol. 91, Iss. 2, pp. 26-28
Closed Access
A Systematic Review and Meta-Analysis of Sodium-Glucose Cotransporter 2 (SGLT-2) Inhibitors and Their Impact on the Management of Heart Failure
Nestor Lemos Ferreira, Abiodun Bamidele Adelowo, Zahid Khan
Cureus (2024)
Open Access
Nestor Lemos Ferreira, Abiodun Bamidele Adelowo, Zahid Khan
Cureus (2024)
Open Access
